6 Reasons Gilead Didn’t Overpay for Kite

Shares of Gilead Sciences (GILD) have been on a steady downward slide since it hit a 52-week high in early September. Last week’s earnings report added another blemish to what has been a disappointing earnings season for Big Biotech. Add to that, some investors remain unconvinced that Gilead didn’t overpay when it bought Kite Pharma […]